Questions Q32.1 How do first- and second-generation antihistamines differ regarding lipophilic properties and anticholinergic effects, and what are the resultant clinical differences? (Pgs. 350, 352) Q32.2 What are the advantages of second-generation over first-generation H 1 antihistamines? (Pgs. 350, 352)…
Questions Q31.1 For which category of patient with atopic dermatitis is dupilumab US Food and Drug Administration (FDA)-approved? (Pg. 339) Q31.2 What are several non-dermatologic conditions for which dupilumab is being considered? (Pg. 340) Q31.3 The exact method of dupilumab…
Questions Q30.1 Rituximab is US Food and Drug Administration (FDA) approved for what dermatologic conditions? What are several categories of dermatoses for which off-label use of rituximab has at least some literature support? (Pg. 331×2) Q30.2 How do the half-lives…
Questions Q29.1 What are the two subunits that make up interleukin (IL)-23? (Pg. 321) Q29.2 What subunit of IL-23 do IL-23 inhibitors target? (Pg. 321) Q29.3 What interleukin inhibitors are directed against IL-23? (Pg. 321) Q29.4 How does the efficacy…
Questions Q28.1 What is the rationale strongly supporting the role of interleukin (IL)-17 in the pathogenesis of psoriasis? (Pg. 312) Q28.2 What is the rationale strongly supporting the role of IL-17 in the pathogenesis of psoriatic arthritis? (Pg. 313) Q28.3…
Questions Q27.1 Which IL 12/23 inhibitor is currently approved for the treatment of psoriasis and which biologics are in development? (Pg. 303) Q27.2 What cytokines are inhibited by ustekinumab? (Pg. 303) Q27.3 Which recently discovered immunopathogenic model for psoriasis has…
Questions Q26.1 What is the rationale strongly supporting the role of TNF-α in the pathogenesis of psoriasis? (Pg. 288) Q26.2 How does TNF-α relate to the Th17 and Th22 pathways? ( Fig. 26.1 ) (Pg. 288) Q26.3 Of the four…
Questions Q25.1 Which anatomic structure is the limiting factor for aminolevulinic acid (ALA) and methyl aminolevulinate (MAL) percutaneous absorption, and what are several measures, which can improve absorption for these products? (Pg. 280) Q25.2 Concerning biochemistry of ALA/MAL, what (1)…
Questions Q24.1 What are the advantages of extracorporeal photopheresis (ECP) systems in which the psoralen is released directly into the treatment mix (vs oral administration)? (Pg. 272) Q24.2 What are the potential cardiovascular and thromboembolic risks of ECP? (Pg. 272)…
Questions Q23.1 What is the pharmacologic importance of food intake and the hepatic ‘first-pass effect’ on methoxsalen bioavailability? (Pg. 264) Q23.2 In which part of the ultraviolet A (UVA) spectrum does methoxsalen have its maximum absorption? (Pg. 264) Q23.3 What…